{
    "clinical_study": {
        "@rank": "131094", 
        "arm_group": {
            "arm_group_label": "PRO-156", 
            "arm_group_type": "Experimental", 
            "description": "Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate safety and tolerability of the ophthalmic solution\n      PRO-156 over the ocular surface of ophthalmologically healthy volunteers"
        }, 
        "brief_title": "Safety and Tolerability of the Ophthalmic Solution PRO-156 in Ophthalmologically Healthy Volunteers.", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "A phase I, open label and unicentric clinical trial to evaluate the safety and tolerability\n      of the ophthalmic solution PRO-143 over the ocular surface of ophthalmologically healthy\n      volunteers."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and female.\n\n          -  Age between 18 and 40 years old at screening visit.\n\n          -  Signed informed consent\n\n        Exclusion Criteria:\n\n          -  Patient with one blind eye.\n\n          -  Any ocular or systemic condition.\n\n          -  Visual acuity of 20/100 in any eye.\n\n          -  Use of ocular or systemics medications.\n\n          -  Contraindications or sensitivity to any component of the study treatment.\n\n          -  Contact lens users.\n\n          -  Ocular surgery within the past 3 months..\n\n          -  Pregnant, nursing or childbearing potential women who were not using effective\n             contraception.\n\n          -  Participation in any studies of investigational drugs within 90 days previous to the\n             inclusion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01871077", 
            "org_study_id": "SOPH156-0612/I"
        }, 
        "intervention": {
            "arm_group_label": "PRO-156", 
            "description": "Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.", 
            "intervention_name": "PRO-156", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 19, 2014", 
        "number_of_arms": "1", 
        "official_title": "Phase I Clinical Trial to Assess the Safety and Tolerability of the Ophthalmic Solution PRO-156 Over the Ocular Surface of Ophthalmologically Healthy Volunteers.", 
        "overall_official": {
            "affiliation": "Independent Clinical Research Center", 
            "last_name": "Mauricio Casillas, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Mexico: Federal Commission for Sanitary Risks Protection", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Evaluate safety of PRO-156 in the ocular surface by the prescence of ocular signs and symptoms,visual acuity (VA), intraocular pressure (IOP), corneal and conjunctival staining (Fluoroscein and lissamine green staining).", 
            "measure": "Safety of PRO-156 ohthalmic solution", 
            "safety_issue": "Yes", 
            "time_frame": "11 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01871077"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Evaluation of ocular symptoms (redness, burning, foreign body sensation, itching, eye discharge and tearing)", 
            "measure": "Tolerability of PRO-156 Ophthalmic Solution", 
            "safety_issue": "No", 
            "time_frame": "11 days"
        }, 
        "source": "Laboratorios Sophia S.A de C.V.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Laboratorios Sophia S.A de C.V.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}